Company intelligence / Profile preview
Jiangsu Leeway Biological Technology
Nanjing, Jiangsu, Chinaleeway-cro.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Jiangsu Leeway Biological Technology has conducted at least one Phase I clinical trial evaluating the pharmacokinetics of topiroxostat in a Chinese population. No additional advanced-stage or commercialized products are reported as of May 2025.
- Therapeutic areas
- Metabolic DisordersRheumatology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Xinjiang Baihuacun Co., Ltd.
Beyond the preview
Go deeper on Jiangsu Leeway Biological Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jiangsu Leeway Biological Technology.